
    
      Patients will receive pembrolizumab and decitabine every 28 days, and a single 3 day course
      of fixed-dose hypofractionated index site radiotherapy to one or more index lesions.

      One cycle lasts 28 days. Radiation is given in Cycle 1 only. Cycles may repeat for a total of
      26 cycles if patient meets criteria to continue protocol therapy.
    
  